Neuronetics (NASDAQ:STIM) Releases Earnings Results, Misses Estimates By $0.05 EPS

Neuronetics (NASDAQ:STIM) issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.05), MarketWatch Earnings reports. The company had revenue of $12.73 million for the quarter, compared to the consensus estimate of $12.72 million. Neuronetics had a negative return on equity of 1,385.60% and a negative net margin of 47.21%. Neuronetics updated its Q2 2019 guidance to EPS and its FY 2019 guidance to EPS.

Shares of STIM opened at $11.33 on Friday. Neuronetics has a one year low of $11.19 and a one year high of $39.39. The stock has a market capitalization of $222.99 million and a PE ratio of -4.21. The company has a quick ratio of 8.74, a current ratio of 8.94 and a debt-to-equity ratio of 0.52.

In other news, insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Thatcher sold 15,000 shares of Neuronetics stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $16.82, for a total transaction of $252,300.00. The disclosure for this sale can be found here. In the last three months, insiders sold 76,571 shares of company stock valued at $1,209,929. Insiders own 12.00% of the company’s stock.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in shares of Neuronetics by 16,237.6% in the 3rd quarter. BlackRock Inc. now owns 408,440 shares of the company’s stock valued at $13,095,000 after buying an additional 405,940 shares in the last quarter. Vanguard Group Inc raised its position in shares of Neuronetics by 1,510.2% in the 3rd quarter. Vanguard Group Inc now owns 241,533 shares of the company’s stock valued at $7,744,000 after buying an additional 226,533 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Neuronetics by 1,510.2% in the 3rd quarter. Vanguard Group Inc. now owns 241,533 shares of the company’s stock valued at $7,744,000 after buying an additional 226,533 shares in the last quarter. Wasatch Advisors Inc. raised its position in shares of Neuronetics by 23.5% in the 1st quarter. Wasatch Advisors Inc. now owns 313,954 shares of the company’s stock valued at $4,788,000 after buying an additional 59,740 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Neuronetics by 76.9% in the 1st quarter. Northern Trust Corp now owns 127,741 shares of the company’s stock valued at $1,948,000 after buying an additional 55,543 shares in the last quarter. Institutional investors and hedge funds own 80.61% of the company’s stock.

A number of research analysts recently weighed in on STIM shares. BTIG Research reaffirmed a “buy” rating and issued a $25.00 target price on shares of Neuronetics in a research report on Wednesday, March 6th. Zacks Investment Research raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Piper Jaffray Companies decreased their target price on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating for the company in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $31.60.

ILLEGAL ACTIVITY WARNING: “Neuronetics (NASDAQ:STIM) Releases Earnings Results, Misses Estimates By $0.05 EPS” was originally posted by Rockland Register and is the sole property of of Rockland Register. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://rocklandregister.com/2019/05/31/neuronetics-stim-issues-earnings-results.html.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Featured Article: Hedge Funds – Risk or Reward?

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.